Klotho Neurosciences rebrands to Greenland Mines, changes ticker to GRML
Klotho Neurosciences Inc. (KLTO) completed its corporate rebranding to Greenland Mines Ltd and changed its stock ticker symbol to GRML, effective at market open on March 12, 2026, according to a company statement.
Existing shareholders will not need to take any action as shares held in brokerage accounts will automatically update to reflect the new symbol. The company operates two divisions: natural resources focused on the Skaergaard Project in Southeast Greenland, and cell and gene therapy including its KLTO-202 treatment for ALS.
Through its recent acquisition of Greenland Mines Corp., the company holds an 80% interest in the Skaergaard Project, with an option to acquire the remaining 20%. The project contains a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 million ounces of palladium equivalent and 23.5 million ounces of gold equivalent.
The company stated the gross undiscounted in-situ resource value is approximately $68 billion based on February 2026 metal prices. These mineral resources have not demonstrated economic viability and no preliminary economic assessment, pre-feasibility study, or feasibility study has been completed on the Skaergaard Project.
Greenland Mines scheduled an investor webcast for March 12, 2026 at 4:15 PM ET to discuss the strategic rationale behind its recent acquisition and potential shareholder benefits.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
